SMMT - Summit Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology) Projected Earnings Date: 2024-08-12    (Delayed quote data   2025-06-30)
Last
 21.28		 Change
 ⇑ +0.68   (+3.30%)		 Volume
  2,136,418
Open
 20.79		 High
 21.31		 Low
 20.33
8EMA (Daily)
 20.87		 40EMA (Daily)
 21.75		 50EMA (Daily)
 21.86		 STO (Daily)
 49.034		 MACD Hist (Daily)
 0.374
8EMA (Weekly)
 21.257		 40EMA (Weekly)
 19.58		 50EMA (Weekly)
 18.52		 STO (Weekly)
 23.464		 MACD Hist (Weekly)
 -0.975
Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has three geographical segments: United States, Latin America, and Europe.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com